PresseBox
Press release BoxID: 158384 (Tecan Group Ltd.)
  • Tecan Group Ltd.
  • Seestrasse 103
  • 8708 Männedorf
  • https://www.tecan.de
  • Contact person
  • Jürgen Fetzer
  • +49 (7951) 9417-618

Invitrogen Corporation Announces Strategic Collaboration with Tecan

Partnership provides integrated instrumentation and reagent solutions

(PresseBox) (Carlsbad, Calif., ) Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and Tecan, a global leader in laboratory automation and detection, are entering into a collaboration agreement to validate the compatibility of Invitrogen s reagents with Tecan s microplate detection instruments.

Invitrogen s drug discovery products will be validated on selected Tecan microplate readers and instruments, starting with the Infinite® series readers. Initial certifications will focus on Invitrogen s assay systems for key target classes, such as LanthaScreen TR-FRET for protein kinases, GeneBLAzer® reporter-gene technology for G protein-coupled receptors and Adapta , a new TR-FRET assay system for lipid kinases. This collaboration will allow Tecan and Invitrogen to develop and promote joint applications for the drug discovery market.

"Through this partnership with Tecan, we will be able to provide integrated instrumentation and reagent solutions to the research community. Previously, this has been a major source of frustration when researchers find that selected technologies are not compatible with the instrument and visa versa," said John Printen, Invitrogen director of cell signaling. "Our goal is to enable researchers to easily select the right Invitrogen assay system for optimum performance on Tecan instruments."

"This program will significantly help researchers in drug discovery and the life sciences to speed up assay development and screening programs. Integrated instrumentation and reagent solutions will make it much easier to rapidly optimize for individual assay conditions, thereby increasing the efficiency of the drug discovery process," said Siegfried Sasshofer, head of sales and marketing for Tecan s detection business.

For more information, visit www.invitrogen.com/drugdiscovery.
For more information about Tecan, visit www.tecan.com


About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com

Tecan Group Ltd.

Tecan (www.tecan.com) is a leading global player in the Life Sciences supply industry specializing in the development, production, and distribution of advanced automation solutions enabling pharma and academic research, diagnostics, food and veterinary research as well as forensics. Through its REMP subsidiary (www.remp.com), Tecan is the leading supplier of compound and sample storage, management and logistics solutions. Tecan clients are pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2005, Tecan achieved sales of CHF 344.9 million (USD 275.9 Mio.; EUR 222.5 Mio.). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN / Reuters: TECZn.S / Valor: 12100191).